重组人组织型纤溶酶原激酶衍生物治疗急性心肌梗死的临床效果分析

目的 研究重组人组织型纤溶酶原激酶衍生物治疗急性心肌梗死（AMI）的临床效果.方法 将140例拟接受溶栓治疗的AMI患者随机分为两组,各70例.观察组给予重组人组织型纤溶酶原激酶衍生物治疗,对照组给予常规尿激酶治疗,对比两组临床治疗效果.结果 治疗后,观察组心肌肌钙蛋白T （cTnT）、肌酸激酶同工酶（CK-MB）水平均低于对照组（P＜0.01）;E峰、E/A值、左心室射血分数（LVEF）、左心室舒张末期直径（LVEDD）均高于对照组（P＜0.01）.结论 重组人组织型纤溶酶原激酶衍生物治疗AMI有助于减少心肌细胞坏死、改善心功能,具有积极的临床价值.

Clinical effect analysis of recombinant human tissue type plasminogen kinase derivatives in treatment of acute myocardial infarction

Objective To study the clinical effect of recombinant human tissue type plasminogen kinase derivatives in treatment of acute myocardial infarction（AMI）. Methods One hundred and forty acute myocardial infarction patients who were to receive thrombolytie therapy were enrolled and randomly divided into observation group （ n = 70）, which was given recombinant human tissue type plasminogen kiuase derivatives and control group（ n = 70） , which was given urokiuas. Then myocardial enzymes and cardiac function were observed. Results The eTnT, CK-MB levels of observation were lower than those of control group（ P 〈 0.01 ）. E peak, E/A value, LVEF, LVEDD were higher than those of control group（ P 〈 0.01 ）. Conclusion Recombinant human tissue type plasminogen kinase derivative treatment has positive clinical value and can reduce myocardial necrosis and improve heart function.